A cross-Unit team will be set up in 2000 to prepare for and initiate associated implementing legislation and in 2001, with the requested staff increase, it may be possible create a dedicated Sector responsible for the Committee on Orphan Medicinal Products and the provision of protocol assistance • provision of operational information to Iceland and Norway, to facilitate their integration into the European procedures • development of working relationships with the national authorities of central and eastern European countries in the framework of the Collaboration Agreement of Drug Regulation Authorities of European Union Associated Countries (CADREAC) and continuation of the PERF exercise